Future Of Psychopharmacology: Is New Treatment Innovation Still Alive?
While past decades saw a boom in the development of innovative new treatments in the field of psychiatry, the pace has slowed in more recent years. In this webinar, Stephen Stahl, MD, PhD discusses the reasons behind the slowing of psychopharmacologic advances in recent years, addresses the importance of targeting symptoms theorized to be caused by inefficiently functioning neurocircuits common to a large array of psychiatric disorders, and examines the future potential for genetic and imaging biomarkers to aid in …